Ovid Therapeutics Q4/FY2024 net loss $26.4M; cash into H2 2026; OV329 data Q3 2025

Ovid Therapeutics Inc.

Net loss $26.4M ($0.37/diluted) for FY2024 vs $52.3M in 2023; royalty revenue $566K.
Cash & securities $53.1M expected to fund operations into H2 2026.
Topline Phase 1 results for OV329 (GABA-AT inhibitor) expected Q3 2025; no SAEs to date.
OV350 (first KCC2 direct activator) began Phase 1 in Q1 2025; topline data expected Q4 2025.
Stelios Papadopoulos appointed to Board; Manal Morsy (Chief Regulatory Officer) and Victoria Fort (Corporate Affairs) joined.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.